Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 279109, 12 pages
http://dx.doi.org/10.1155/2015/279109
Research Article

Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China
2Department of Clinical Laboratory, Shengjing Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110003, China
3Department of Clinical Laboratory, The First Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China
4Institute of Pathology and Pathophysiology, The First Hospital and College of Basic Medical Sciences of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China

Received 8 June 2015; Revised 13 September 2015; Accepted 12 October 2015

Academic Editor: Siddharth Pratap

Copyright © 2015 Huizhe Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Desantis, R. Siegel, P. Bandi, and A. Jemal, “Breast cancer statistics, 2011,” CA: A Cancer Journal for Clinicians, vol. 61, no. 6, pp. 409–418, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. E. R. Lepper, K. Nooter, J. Verweij, M. R. Acharya, W. D. Figg, and A. Sparreboom, “Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABC1 and ABCG2,” Pharmacogenomics, vol. 6, no. 2, pp. 115–138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Ishikawa and H. Nakagawa, “Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics,” Journal of Experimental Therapeutics and Oncology, vol. 8, no. 1, pp. 5–24, 2009. View at Google Scholar · View at Scopus
  4. K. Noguchi, K. Katayama, J. Mitsuhashi, and Y. Sugimoto, “Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy,” Advanced Drug Delivery Reviews, vol. 61, no. 1, pp. 26–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Han and J.-T. Zhang, “Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2,” Current Medicinal Chemistry—Anti-Cancer Agents, vol. 4, no. 1, pp. 31–42, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Krishnamurthy and J. D. Schuetz, “Role of ABCG2/BCRP in biology and medicine,” Annual Review of Pharmacology and Toxicology, vol. 46, pp. 381–410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Doyle, W. Yang, L. V. Abruzzo et al., “A multidrug resistance transporter from human MCF-7 breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15665–15670, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Sugimoto, S. Tsukahara, E. Ishikawa, and J. Mitsuhashi, “Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics,” Cancer Science, vol. 96, no. 8, pp. 457–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Cusatis and A. Sparreboom, “Pharmacogenomic importance of ABCG2,” Pharmacogenomics, vol. 9, no. 8, pp. 1005–1009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. S. Lee, H.-E. Jeong, J.-M. Yi et al., “Identification and functional assessment of BCRP polymorphisms in a Korean population,” Drug Metabolism & Disposition, vol. 35, no. 4, pp. 623–632, 2007. View at Publisher · View at Google Scholar
  11. K.-A. Kim, H.-J. Joo, and J.-Y. Park, “ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations,” Journal of Clinical Pharmacy and Therapeutics, vol. 35, no. 6, pp. 705–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bäckström, J. Taipalensuu, H. Melhus et al., “Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population,” European Journal of Pharmaceutical Sciences, vol. 18, no. 5, pp. 359–364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. M. Bosch, L. M. Kjellberg, A. Bouwers et al., “Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population,” American Journal of PharmacoGenomics, vol. 5, no. 2, pp. 123–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Imai, M. Nakane, K. Kage et al., “C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance,” Molecular Cancer Therapeutics, vol. 1, no. 8, pp. 611–616, 2002. View at Google Scholar · View at Scopus
  15. C. P. Zamber, J. K. Lamba, K. Yasuda et al., “Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine,” Pharmacogenetics, vol. 13, no. 1, pp. 19–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Kasza, G. Várady, H. Andrikovics et al., “Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations,” PLoS ONE, vol. 7, no. 11, Article ID e48423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Kobayashi, I. Ieiri, T. Hirota et al., “Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta,” Drug Metabolism and Disposition, vol. 33, no. 1, pp. 94–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Korenaga, K. Naito, N. Okayama et al., “Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma,” International Journal of Cancer, vol. 117, no. 3, pp. 431–434, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. N. M. Hahn, S. Marsh, W. Fisher et al., “Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis,” Clinical Cancer Research, vol. 12, no. 20, part 1, pp. 6094–6099, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-Y. Han, H.-S. Lim, Y.-K. Yoo et al., “Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer,” Cancer, vol. 110, no. 1, pp. 138–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L.-L. Hu, X.-X. Wang, X. Chen et al., “BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma,” Carcinogenesis, vol. 28, no. 8, pp. 1740–1744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Müller, H. Dally, C. N. Klappenecker et al., “Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients,” International Journal of Cancer, vol. 124, no. 7, pp. 1669–1674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Campa, K. Butterbach, S. L. Slager et al., “A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk,” International Journal of Cancer, vol. 131, no. 4, pp. 803–812, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Allikmets, L. M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean, “A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance,” Cancer Research, vol. 58, no. 23, pp. 5337–5339, 1998. View at Google Scholar · View at Scopus
  25. T. Litman, T. E. Druley, W. D. Stein, and S. E. Bates, “From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance,” Cellular and Molecular Life Sciences, vol. 58, no. 7, pp. 931–959, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. D. D. Ross and T. Nakanishi, “Impact of breast cancer resistance protein on cancer treatment outcomes,” in Multi-Drug Resistance in Cancer, vol. 596 of Methods in Molecular Biology, pp. 251–290, Humana Press, 2010. View at Publisher · View at Google Scholar
  27. S. Choudhuri and C. Klaassen, “Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters,” International Journal of Toxicology, vol. 25, no. 4, pp. 231–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Ieiri, “Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2),” Drug Metabolism and Pharmacokinetics, vol. 27, no. 1, pp. 85–105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. E. K. Pollex, G. Anger, J. Hutson, G. Koren, and M. Piquette-Miller, “Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism,” Drug Metabolism and Disposition, vol. 38, no. 5, pp. 740–744, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Mizuarai, N. Aozasa, and H. Kotani, “Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2,” International Journal of Cancer, vol. 109, no. 2, pp. 238–246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Furukawa, K. Wakabayashi, A. Tamura et al., “Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations,” Pharmaceutical Research, vol. 26, no. 2, pp. 469–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Nakanishi and D. D. Ross, “Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression,” Chinese Journal of Cancer, vol. 31, no. 2, pp. 73–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Kondo, H. Suzuki, M. Itoda et al., “Functional analysis of SNPs variants of BCRP/ABCG2,” Pharmaceutical Research, vol. 21, no. 10, pp. 1895–1903, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Yanase, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto, “Functional SNPs of the breast cancer resistance protein—therapeutic effects and inhibitor development,” Cancer Letters, vol. 234, no. 1, pp. 73–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Sarankó, H. Tordai, Á. Telbisz et al., “Effects of the gout-causing Q141K polymorphism and a CFTR δF508 mimicking mutation on the processing and stability of the ABCG2 protein,” Biochemical and Biophysical Research Communications, vol. 437, no. 1, pp. 140–145, 2013. View at Publisher · View at Google Scholar · View at Scopus